Actively Recruiting
The Organ Transplant Recipient HPV and Skin Cancer Study
Led by Merete Haedersdal · Updated on 2025-04-01
1500
Participants Needed
3
Research Sites
1094 weeks
Total Duration
On this page
Sponsors
M
Merete Haedersdal
Lead Sponsor
D
Danish Cancer Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers. In particular, OTRs have increased risk of skin cancer and cancers caused by human papillomavirus (HPV), including cervical cancer and oropharyngeal cancer. There is currently limited knowledge on risk factors for HPV infection and skin cancer in OTRs, and limited knowledge on the natural history of HPV infection and cervical neoplasia in OTRs compared with immunocompetent controls. With a continuously increasing number of OTRs, there is a growing need to improve our understanding of the long-term reactions to immunosuppression. The overall aim of this study is to investigate long term effects of immunosuppression on cutaneous and mucosal epithelium in Danish OTRs, including the risk of skin dysplasia and skin cancer, cervical and oral HPV infection and HPV-related dysplasia and cancer in OTRs. This study will be designed as a prospective observational cohort study based on clinical data and data from nationwide Danish registries. A total of 600 female OTRs, 300 male OTRs and 600 female controls will be included from Danish dermatology departments. The study aims to provide knowledge relevant for improving prevention of skin- and HPV-related cancers in OTRs, including personalized screening recommendations according to individual patient risk.
CONDITIONS
Official Title
The Organ Transplant Recipient HPV and Skin Cancer Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 2518 years
- Solid organ transplantation recipients, including kidney, liver, lung, and heart transplant recipients
- Stable immunosuppressive treatment for at least 3 months
- No signs of acute graft rejection
- Patients who reside in Denmark
- Informed written consent obtained
- Able patients aged 2518 years (for control group)
- No known immunosuppressive therapy or condition (for control group)
- Patients who reside in Denmark (for control group)
- Informed written consent obtained (for control group)
You will not qualify if you...
- Patients with concomitant bone marrow transplantation
- Full hysterectomy
- Full hysterectomy (for control group)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Department of Dermatology, Bispebjerg Hospital
Copenhagen NV, Capital Region, Denmark, 2400
Actively Recruiting
2
Department of Dermatology and Allergy, Herlev og Gentofte Hospital
Hellerup, Capital Region, Denmark, 2900
Actively Recruiting
3
Department of Dermatology, Zealand University Hospital
Roskilde, Region Sjælland, Denmark, 4000
Actively Recruiting
Research Team
L
Lene Rask
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here